HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents

Antivir Ther. 2012;17(6 Pt B):1133-46. doi: 10.3851/IMP2425. Epub 2012 Oct 5.

Abstract

Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past months, important steps have been made towards a more effective antiviral therapy. However, we are still far from both highly efficient and well-tolerable ideal therapy. The development of new drugs against HCV is a very dynamic field. This review summarizes the up-to-date knowledge of the most significant anti-HCV compounds in development.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Cyclophilins / antagonists & inhibitors
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Hepacivirus / drug effects*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • MicroRNAs / antagonists & inhibitors
  • Viral Nonstructural Proteins / antagonists & inhibitors
  • Viral Structures / drug effects
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Immunologic Factors
  • MicroRNAs
  • Viral Nonstructural Proteins
  • Cyclophilins